PLUS Therapeutics (PSTV) director converts RSUs into 922 common shares

Rhea-AI Filing Summary

PLUS THERAPEUTICS, INC. director Kyle Guse exercised restricted stock units to acquire 922 shares of Common Stock at no cost. After the transaction, he directly holds 922 Common shares. A related RSU grant totaling 2,764 units remains outstanding and vests in four substantially equal quarterly installments beginning on July 1, 2026.

Insider Trade Summary

922 shares exercised/converted

Mixed 2 txns

Insider Guse Kyle

Role null

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	922	$0.00	--
Exercise	Common Stock	922	$0.00	--

Holdings After Transaction: Restricted Stock Units — 2,764 shares (Direct, null); Common Stock — 922 shares (Direct, null)

Footnotes (1)

1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the issuer's Common Stock. Represents the vesting of an RSU grant which occurs in four substantially equal quarterly installments beginning on July 1, 2026.

Key Figures

Common shares acquired: 922 shares Exercise price: $0.00 per share Common shares held after: 922 shares +2 more

5 metrics

Common shares acquired 922 shares Common Stock received from RSU exercise on July 1, 2026

Exercise price $0.00 per share Price for 922 Common shares issued from RSUs

Common shares held after 922 shares Direct ownership following the reported transaction

RSUs outstanding 2,764 units Restricted Stock Units remaining after the transaction

RSU vesting schedule Four equal quarterly installments Vesting begins on July 1, 2026

Key Terms

Restricted Stock Unit, derivative security, vests in four substantially equal quarterly installments

3 terms

Restricted Stock Unit financial

"Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

derivative security financial

"transaction_code_description": "Exercise or conversion of derivative security""

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

vests in four substantially equal quarterly installments financial

"Represents the vesting of an RSU grant which occurs in four substantially equal quarterly installments"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/01/2026 - 04:31 PM Accepted by SEC EDGAR 07/01/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Guse Kyle

(Last) (First) (Middle)

C/O PLUS THERAPEUTICS INC.

6420 LEVIT GREEN BOULEVARD, SUITE 310

(Street)

HOUSTON TEXAS 77021

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PLUS THERAPEUTICS, INC. [ PSTV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/01/2026		M		922(2)	A	$0(1)	922	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	07/01/2026		M			922	(2)	(2)	Common Stock	922	$0	2,764	D

Explanation of Responses:

1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the issuer's Common Stock.

2. Represents the vesting of an RSU grant which occurs in four substantially equal quarterly installments beginning on July 1, 2026.

	Andrew Sims, as attorney-in-fact	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did PSTV director Kyle Guse report on this Form 4?

Kyle Guse reported exercising restricted stock units to acquire 922 shares of PLUS THERAPEUTICS Common Stock at a per-share price of $0.00. This transaction reflects the conversion of derivative RSU awards into directly held common shares as part of his equity compensation.

How many PLUS THERAPEUTICS (PSTV) shares does Kyle Guse hold after this transaction?

Following the reported transaction, Kyle Guse directly holds 922 shares of PLUS THERAPEUTICS Common Stock. These holdings result from the exercise of restricted stock units and represent his reported direct ownership position as of the transaction date disclosed in the Form 4.

What happens to Kyle Guse’s remaining Restricted Stock Units in PSTV?

A restricted stock unit grant of 2,764 units remains outstanding for Kyle Guse. According to the disclosure, these RSUs vest in four substantially equal quarterly installments beginning on July 1, 2026, each unit representing a contingent right to receive one share of Common Stock.

What does the $0.00 exercise price mean for the PSTV RSU transaction?

The $0.00 exercise price indicates Kyle Guse did not pay cash to convert restricted stock units into 922 Common shares. RSUs typically settle into shares upon vesting based on service or performance conditions, functioning as equity compensation rather than a cash investment purchase.

Is this PLUS THERAPEUTICS (PSTV) Form 4 an open-market buy or sale?

This Form 4 does not report an open-market buy or sale. It records the exercise of restricted stock units, a derivative security, resulting in the issuance of 922 Common shares to Kyle Guse as equity compensation, without any reported market purchase or sale transaction.